Perspective Therapeutics reports FY2024 net loss $79.3M; cash $227M; VMT-α-NET enrollment reaches 30 patients

Perspective Therapeutics, Inc.

Net loss of $79.3M ($1.23 loss per share) vs $46.5M in FY2023; R&D spend doubled to $41.6M.
Goodwill impairment of $24.1M due to low market cap; cash and investments $227M, funding expected into late 2026.
VMT-α-NET Phase 1/2a enrolled 30 patients in Cohort 2 as of Feb 2025; no DLTs, one confirmed response.
IND cleared for PSV359 (FAP-α targeting); first patient dosing expected mid-2025.
In Feb 2025, sold 3.38M shares under ATM at ~$3.02 for gross proceeds of $10.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.